Canonical URL: https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/ --- description: Bolt Pharmacy’s digital journey separates initial assessment, professional review and payment. For AIOS, process clarity forms part of acquisition. title: AIOS and Bolt: a three-minute promise needs to explain the review that follows image: https://elacelerador.es/images/social/v1/aios-bolt-three-minute-promise-needs-explain-review-follows-55954575ceb982d89e1d80bc61e95fd0.jpg --- 1. [Home](https://elacelerador.es/en/) 2. [Cases and research](https://elacelerador.es/en/cases-and-research/) # AIOS and Bolt: a three-minute promise needs to explain the review that follows Bolt separates initial assessment, professional review and payment. For AIOS, explaining each step aligns acquisition promises with the service that follows. By [Marian Vasile](https://elacelerador.es/en/author/marian-vasile/) 17 October 2026 at 22:36 CEST 5 min read [ Add as preferred source ](https://www.google.com/preferences/source?q=elacelerador.es&utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) Share [ ](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Felacelerador.es%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F%3Futm%5Fsource%3Dlinkedin%26utm%5Fmedium%3Dsocial&utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es "Share on LinkedIn. Preview requests: 0") [ ](https://wa.me/?text=AIOS+and+Bolt%3A+a+three-minute+promise+needs+to+explain+the+review+that+follows+https%3A%2F%2Felacelerador.es%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F%3Futm%5Fsource%3Dwhatsapp%26utm%5Fmedium%3Dsocial&utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es "Share on WhatsApp. Preview requests: 0") [ ](https://t.me/share/url?url=https%3A%2F%2Felacelerador.es%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F%3Futm%5Fsource%3Dtelegram%26utm%5Fmedium%3Dsocial&text=AIOS+and+Bolt%3A+a+three-minute+promise+needs+to+explain+the+review+that+follows&utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es "Share on Telegram. Preview requests: 0") [ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Felacelerador.es%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F%3Futm%5Fsource%3Dfacebook%26utm%5Fmedium%3Dsocial&utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es "Share on Facebook. Preview requests: 0") ![Shelves of personal care products and chairs inside a pharmacy.](https://elacelerador.es/images/variants/v1/aios-bolt-three-minute-promise-needs-explain-review-follows-shelves-personal-care-w1280.webp) Interior of Sunlight Pharmacy in Gillingham, United Kingdom, photographed by Sunolafjagtenben-hur on April 7, 2025\. Context photograph of pharmacy retail; it does not show Bolt Pharmacy or AIOS facilities. Photo: [Sunolafjagtenben-hur / Wikimedia Commons, CC0 1.0](https://commons.wikimedia.org/wiki/File:Interior%5Fof%5FSunlight%5FPharmacy,%5F105%5FRichmond%5FRoad,%5FGillingham%5FME71LX%5F-%5FMedway.jpg?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) **In this report** 1. [The speed promise ends where review begins](#article-section-the-speed-promise-ends-where-review-begins) 2. [Digital supply is counted in premises, not patients](#article-section-digital-supply-is-counted-in-premises-not-patients) 3. [NHS prescription activity follows a different business model](#article-section-nhs-prescription-activity-follows-a-different-business-model) 4. [Commercial trust needs verifiable states](#article-section-commercial-trust-needs-verifiable-states) 2 figures * [Pharmacies offering online services: supply was growing before 2023](#article-figure-1) * [Active NHS distance selling pharmacies in England](#article-figure-2) [Download data (CSV)](https://elacelerador.es/en/download.csv?article=%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F) Chart values, table cells, source references and the report revision date. At an online pharmacy, completing a form and receiving clinical approval are different steps. Bolt Pharmacy advertises an initial assessment taking about three minutes; its service explanation then describes a consultation with a professional who decides whether treatment is appropriate. For AIOS, which participates in the digital journey’s technology, the acquisition message needs to keep that distinction clear through to payment. Bolt’s homepage uses the speed of entry as one of its commercial promises. Its FAQ clarifies that information goes to a prescriber and that assessment is not completed through the questionnaire alone. Sustainable growth in this journey means helping people understand and complete the process they need, without confusing the first step with a decision that has not yet been made. This detail matters because each step creates a different expectation. A visitor needs to know what to provide; someone who has submitted information needs to understand what is missing and who will respond; someone receiving a decision needs to know its consequences for the order and payment. Commercial design becomes more precise when it explains these changes of state. ## The speed promise ends where review begins In its FAQ on how the service works , Bolt distinguishes initial assessment, two-way consultation, the prescriber’s decision and dispensing. It also states that people who are not approved will be notified and will not be charged. This is a specific commercial condition: users should understand it before submitting their information and interpreting a form as a confirmed purchase. Improving the journey does not require everyone to progress to a sale. It requires each person to understand their actual situation. When information is missing, the next action should request it; when a professional is involved, the interface should explain that review remains pending. A low purchase proportion can have causes very different from a problem with the page. Measuring these steps separately allows a more careful assessment of acquisition. The cost of attracting a request, the work required to complete it and the cost of serving an approved order affect service economics at different moments. Bolt’s internal values are not known here, so there is no basis for attributing abandonment rates or estimating gains from changing a screen. ## Digital supply is counted in premises, not patients Historical context shows that many premises offered online services before the recent expansion of private consultations. GPhC figures published by C+D and recorded by Statista count 519 pharmacies with online services in Great Britain at the end of 2018 and 680 at the end of 2022. The data behind the story ### Pharmacies offering online services: supply was growing before 2023 Historical GPhC figures reported by C+D and recorded by Statista. Selects year-end observations from 2018 to 2022. Pharmacies pharmacies Tap or hover for details. All values are also available in the data table. Expand notesCollapse notes **Sources:** Statista; C+D: GPhC data table Counts premises, not patients, sales, market share or clinical quality. GPhC regulates Great Britain; Statista labels the series United Kingdom. Excludes 2023 because the C+D publication date conflicts with the date assigned to that observation. Not directly comparable with the NHS category in the second chart. Explore the data table Scroll left or right to see all columns __Pharmacies offering online services: supply was growing before 2023 (pharmacies)__ | Category | Pharmacies | | -------- | -------------- | | 2018 | 519 pharmacies | | 2019 | 578 pharmacies | | 2020 | 619 pharmacies | | 2021 | 653 pharmacies | | 2022 | 680 pharmacies | This growth describes supply and channel availability. It does not demonstrate an equivalent increase in patients, revenue or demand for Bolt’s particular service. For a brand, competing through an established channel makes a recognizable explanation of what follows the click more valuable: what is reviewed, who responds and when the order is confirmed. ## NHS prescription activity follows a different business model The second series, from NHSBSA and distributed by Statista, counts distance selling pharmacies active in England’s NHS reimbursed-prescription system. It rose from 372 in 2020/21 to 430 in 2024/25\. The figure identifies a category of contracting and activity, rather than every pharmacy with a website. The data behind the story ### Active NHS distance selling pharmacies in England An NHS administrative category, distinct from all pharmacies offering online services. Financial years. Pharmacies pharmacies Tap or hover for details. All values are also available in the data table. Expand notesCollapse notes **Sources:** Statista; NHSBSA: original table 2 Contractors submitting prescriptions to the NHS for reimbursement at some point during the financial year, classified as distance selling at March 31\. Not all online pharmacies or a count of private consultations. Values come from the 2024/25 release, not the current 2026 inventory. They are not attributed to Bolt or AIOS. Explore the data table Scroll left or right to see all columns __Active NHS distance selling pharmacies in England (pharmacies)__ | Category | Pharmacies | | -------- | -------------- | | 2020/21 | 372 pharmacies | | 2021/22 | 375 pharmacies | | 2022/23 | 398 pharmacies | | 2023/24 | 409 pharmacies | | 2024/25 | 430 pharmacies | The two charts help avoid a common commercial confusion. Operating online does not by itself define who pays, what service is supplied or how care is organized. The opportunity for a private consultation cannot be calculated from the number of NHS contractors. Its acquisition, follow-up and dispensing costs need their own explanation. Bolt’s privacy policy , updated on October 2, 2026, distinguishes Bolt Healthcare Ltd, AIOS Technology Ltd for clinical functions and Aios LLC for platform, support and marketing functions. This division of tasks allows the journey to be explained through specific responsibilities, without allowing a trading name to replace information about who is involved. ## Commercial trust needs verifiable states The CQC register entry for AIOS Technology Ltd states that the service registered on January 23, 2026 and has not yet been inspected. Registration and a subsequent assessment are different facts. Commercial presentation needs to preserve that precision when it uses trust signals. AIOS’s priority is to make the entry message, instructions and final confirmation describe the same service. Useful communication preserves the request’s context and shows the next action without requiring users to infer whether they are completing a form, attending a consultation or placing an order. A change should be judged by whether it clarifies that step and reduces avoidable work while preserving professional responsibility for the clinical decision. The economic advantage of a digital journey does not come from presenting every review as unnecessary friction. It comes from reserving the appropriate intervention for the point that needs it and clearly explaining what technology can already handle. For AIOS and Bolt, better acquisition begins with ensuring that a three-minute promise does not erase what follows. [Back to top ↑](#article-top) ## In this article ### Sources and documents * [Bolt: the digital journey begins](https://www.boltpharmacy.co.uk/?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) · Bolt Pharmacy * [Bolt: assessment, consultation and payment timing](https://www.boltpharmacy.co.uk/faq?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) · Bolt Pharmacy * [Bolt: platform and consultation responsibilities](https://www.boltpharmacy.co.uk/privacy?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) · Bolt Healthcare Ltd * Statista * [C+D: historical figures attributed to GPhC](https://www.chemistanddruggist.co.uk/CD137252/Do-online-pharmacies-face-a-profitable-future/?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) · Chemist + Druggist * [GPhC: regulatory remit in Great Britain](https://inspections.pharmacyregulation.org/about-us?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) · General Pharmaceutical Council * [NHSBSA: 2024/25 release and original tables](https://www.nhsbsa.nhs.uk/statistical-collections/general-pharmaceutical-services-england/general-pharmaceutical-services-england-201516-202425?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) · NHS Business Services Authority * [NHSBSA: definitions and methodology](https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/gphs/gphs%5Fbackground%5Fv001.html?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) · NHS Business Services Authority * [CQC: AIOS Technology Ltd service registration](https://www.cqc.org.uk/location/1-25516432019?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) · Care Quality Commission * [NHSBSA: original table 2](https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/gphs/gps%5F2425%5Fsummary%5Ftables%5Fv001.xlsx?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) Share [ ](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Felacelerador.es%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F%3Futm%5Fsource%3Dlinkedin%26utm%5Fmedium%3Dsocial&utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es "Share on LinkedIn. Preview requests: 0") [ ](https://wa.me/?text=AIOS+and+Bolt%3A+a+three-minute+promise+needs+to+explain+the+review+that+follows+https%3A%2F%2Felacelerador.es%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F%3Futm%5Fsource%3Dwhatsapp%26utm%5Fmedium%3Dsocial&utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es "Share on WhatsApp. Preview requests: 0") [ ](https://t.me/share/url?url=https%3A%2F%2Felacelerador.es%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F%3Futm%5Fsource%3Dtelegram%26utm%5Fmedium%3Dsocial&text=AIOS+and+Bolt%3A+a+three-minute+promise+needs+to+explain+the+review+that+follows&utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es "Share on Telegram. Preview requests: 0") [ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Felacelerador.es%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F%3Futm%5Fsource%3Dfacebook%26utm%5Fmedium%3Dsocial&utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es "Share on Facebook. Preview requests: 0") ![Portrait of Marian Vasile](https://elacelerador.es/images/variants/v1/marian-vasile-autor-acelerador-retrato-w320.webp) [LinkedIn](https://www.linkedin.com/in/nairamelisav/?utm%5Fsource=elacelerador.es&utm%5Fcampaign=elacelerador.es) About the author ## [Marian Vasile](https://elacelerador.es/en/author/marian-vasile/) Marian Vasile is a MarTech and growth professional. His work spans product marketing, SEO, paid advertising and deep online tracking, including behavioral analytics and attribution. ## Related articles [Cases and research](https://elacelerador.es/en/cases-and-research/) Analysis ### [SHIELD: a coupon’s cost depends on who claims it again](https://elacelerador.es/en/cases-and-research/shield-coupon-cost-accounts-legitimate-customers/) [Marian Vasile](https://elacelerador.es/en/author/marian-vasile/) 17 October 2026 6 min [Cases and research](https://elacelerador.es/en/cases-and-research/) Analysis ### [Safeguard Global: the calculator pricing two routes to expansion](https://elacelerador.es/en/cases-and-research/safeguard-global-calculator-eor-entity-expansion-cost/) [Marian Vasile](https://elacelerador.es/en/author/marian-vasile/) 17 October 2026 6 min [Cases and research](https://elacelerador.es/en/cases-and-research/) Analysis ### [GRC Media: financing a section is only the start of a renewable partnership](https://elacelerador.es/en/cases-and-research/grc-media-financing-section-renewing-partnership/) [Marian Vasile](https://elacelerador.es/en/author/marian-vasile/) 17 October 2026 5 min **In this report** 1. [The speed promise ends where review begins](#article-section-the-speed-promise-ends-where-review-begins) 2. [Digital supply is counted in premises, not patients](#article-section-digital-supply-is-counted-in-premises-not-patients) 3. [NHS prescription activity follows a different business model](#article-section-nhs-prescription-activity-follows-a-different-business-model) 4. [Commercial trust needs verifiable states](#article-section-commercial-trust-needs-verifiable-states) [Download data (CSV)](https://elacelerador.es/en/download.csv?article=%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F) [Back to top ↑](#article-top) ## Related articles [Cases and research](https://elacelerador.es/en/cases-and-research/) Analysis ### [SHIELD: a coupon’s cost depends on who claims it again](https://elacelerador.es/en/cases-and-research/shield-coupon-cost-accounts-legitimate-customers/) [Marian Vasile](https://elacelerador.es/en/author/marian-vasile/) 17 October 2026 6 min [Cases and research](https://elacelerador.es/en/cases-and-research/) Analysis ### [Safeguard Global: the calculator pricing two routes to expansion](https://elacelerador.es/en/cases-and-research/safeguard-global-calculator-eor-entity-expansion-cost/) [Marian Vasile](https://elacelerador.es/en/author/marian-vasile/) 17 October 2026 6 min [Cases and research](https://elacelerador.es/en/cases-and-research/) Analysis ### [GRC Media: financing a section is only the start of a renewable partnership](https://elacelerador.es/en/cases-and-research/grc-media-financing-section-renewing-partnership/) [Marian Vasile](https://elacelerador.es/en/author/marian-vasile/) 17 October 2026 5 min ```json {"@context":"https://schema.org","@graph":[{"@type":["Organization","NewsMediaOrganization"],"@id":"https://elacelerador.es/#publisher","name":"El Acelerador","url":"https://elacelerador.es/","description":"Marketing and growth hacking with examples from Spanish companies.","email":"pr@elacelerador.es","publishingPrinciples":"https://elacelerador.es/en/editorial-policy/","correctionsPolicy":"https://elacelerador.es/en/editorial-policy/","verificationFactCheckingPolicy":"https://elacelerador.es/en/editorial-policy/","masthead":"https://elacelerador.es/en/about/","ownershipFundingInfo":"https://elacelerador.es/en/about/","logo":{"@type":"ImageObject","url":"https://elacelerador.es/icon-512.png?v=20261017-stacked"}},{"@type":"Person","@id":"https://elacelerador.es/author/marian-vasile/#person","name":"Marian Vasile","url":"https://elacelerador.es/en/author/marian-vasile/","description":"Marian Vasile is a MarTech and growth professional. His work spans product marketing, SEO, paid advertising and deep online tracking, including behavioral analytics and attribution.","sameAs":["https://marianvasile.com/","https://www.linkedin.com/in/nairamelisav/"],"image":{"@type":"ImageObject","url":"https://elacelerador.es/images/marian-vasile-autor-acelerador-retrato.webp","contentUrl":"https://elacelerador.es/images/marian-vasile-autor-acelerador-retrato.webp","width":519,"height":519,"caption":"Marian Vasile"}},{"@type":"ImageObject","url":"https://elacelerador.es/images/aios-bolt-three-minute-promise-needs-explain-review-follows-shelves-personal-care.webp","contentUrl":"https://elacelerador.es/images/aios-bolt-three-minute-promise-needs-explain-review-follows-shelves-personal-care.webp","width":1440,"height":1920,"caption":"Interior of Sunlight Pharmacy in Gillingham, United Kingdom, photographed by Sunolafjagtenben-hur on April 7, 2025. Context photograph of pharmacy retail; it does not show Bolt Pharmacy or AIOS facilities.","@id":"https://elacelerador.es/images/aios-bolt-three-minute-promise-needs-explain-review-follows-shelves-personal-care.webp#image","creditText":"Sunolafjagtenben-hur / Wikimedia Commons, CC0 1.0","isBasedOn":"https://commons.wikimedia.org/wiki/File:Interior_of_Sunlight_Pharmacy,_105_Richmond_Road,_Gillingham_ME71LX_-_Medway.jpg"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-1","name":"Bolt: the digital journey begins","url":"https://www.boltpharmacy.co.uk/","creditText":"Bolt Pharmacy"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-2","name":"Bolt: assessment, consultation and payment timing","url":"https://www.boltpharmacy.co.uk/faq","creditText":"Bolt Pharmacy"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-3","name":"Bolt: platform and consultation responsibilities","url":"https://www.boltpharmacy.co.uk/privacy","creditText":"Bolt Healthcare Ltd"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-4","name":"Statista","url":"https://www.statista.com/"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-5","name":"C+D: historical figures attributed to GPhC","url":"https://www.chemistanddruggist.co.uk/CD137252/Do-online-pharmacies-face-a-profitable-future/","creditText":"Chemist + Druggist"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-6","name":"GPhC: regulatory remit in Great Britain","url":"https://inspections.pharmacyregulation.org/about-us","creditText":"General Pharmaceutical Council"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-7","name":"NHSBSA: 2024/25 release and original tables","url":"https://www.nhsbsa.nhs.uk/statistical-collections/general-pharmaceutical-services-england/general-pharmaceutical-services-england-201516-202425","creditText":"NHS Business Services Authority"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-8","name":"NHSBSA: definitions and methodology","url":"https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/gphs/gphs_background_v001.html","creditText":"NHS Business Services Authority"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-9","name":"CQC: AIOS Technology Ltd service registration","url":"https://www.cqc.org.uk/location/1-25516432019","creditText":"Care Quality Commission"},{"@type":"CreativeWork","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-10","name":"NHSBSA: original table 2","url":"https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/gphs/gps_2425_summary_tables_v001.xlsx"},{"@type":"Dataset","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#dataset","url":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-top","name":"The data behind the story: AIOS and Bolt: a three-minute promise needs to explain the review that follows","description":"Data accompanying the article, with the published research figures, tables, sources and methodological notes. The CSV download contains the complete article data export.","inLanguage":"en-GB","isPartOf":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article","hasPart":[{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-figure-1-dataset"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-figure-2-dataset"}],"isAccessibleForFree":false,"isBasedOn":["https://www.statista.com/","https://www.chemistanddruggist.co.uk/CD137252/Do-online-pharmacies-face-a-profitable-future/","https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/gphs/gps_2425_summary_tables_v001.xlsx"],"publisher":{"@id":"https://elacelerador.es/#publisher"},"distribution":{"@type":"DataDownload","name":"Download data (CSV)","contentUrl":"https://elacelerador.es/en/download.csv?article=%2Fen%2Fcases-and-research%2Faios-bolt-consultation-approval-conversion%2F","encodingFormat":"text/csv","requiresSubscription":true,"isAccessibleForFree":false}},{"@type":"Dataset","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-figure-1-dataset","url":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-figure-1","name":"Pharmacies offering online services: supply was growing before 2023","description":"Historical GPhC figures reported by C+D and recorded by Statista. Selects year-end observations from 2018 to 2022. Counts premises, not patients, sales, market share or clinical quality. GPhC regulates Great Britain; Statista labels the series United Kingdom. Excludes 2023 because the C+D publication date conflicts with the date assigned to that observation. Not directly comparable with the NHS category in the second chart.","inLanguage":"en-GB","isPartOf":{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#dataset"},"isAccessibleForFree":false,"publisher":{"@id":"https://elacelerador.es/#publisher"},"variableMeasured":[{"@type":"PropertyValue","name":"Pharmacies","unitText":"pharmacies"}],"isBasedOn":["https://www.statista.com/","https://www.chemistanddruggist.co.uk/CD137252/Do-online-pharmacies-face-a-profitable-future/"]},{"@type":"Dataset","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-figure-2-dataset","url":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-figure-2","name":"Active NHS distance selling pharmacies in England","description":"An NHS administrative category, distinct from all pharmacies offering online services. Financial years. Contractors submitting prescriptions to the NHS for reimbursement at some point during the financial year, classified as distance selling at March 31. Not all online pharmacies or a count of private consultations. Values come from the 2024/25 release, not the current 2026 inventory. They are not attributed to Bolt or AIOS.","inLanguage":"en-GB","isPartOf":{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#dataset"},"isAccessibleForFree":false,"publisher":{"@id":"https://elacelerador.es/#publisher"},"variableMeasured":[{"@type":"PropertyValue","name":"Pharmacies","unitText":"pharmacies"}],"isBasedOn":["https://www.statista.com/","https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/gphs/gps_2425_summary_tables_v001.xlsx"]},{"@type":"Article","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article","url":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/","headline":"AIOS and Bolt: a three-minute promise needs to explain the review that follows","description":"Bolt Pharmacy’s digital journey separates initial assessment, professional review and payment. For AIOS, process clarity forms part of acquisition.","datePublished":"2026-10-17T20:36:08.539Z","dateModified":"2026-10-17T20:36:08.539Z","inLanguage":"en-GB","mainEntityOfPage":{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#webpage"},"translationOfWork":{"@id":"https://elacelerador.es/casos-y-estudios/aios-bolt-consulta-aprobacion-conversion/#article"},"isPartOf":{"@id":"https://elacelerador.es/en/#website"},"isAccessibleForFree":false,"hasPart":[{"@type":"WebPageElement","isAccessibleForFree":false,"cssSelector":".reader-restricted"}],"image":[{"@id":"https://elacelerador.es/images/aios-bolt-three-minute-promise-needs-explain-review-follows-shelves-personal-care.webp#image"}],"articleSection":"Cases and research","wordCount":994,"timeRequired":"PT5M","citation":[{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-1"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-2"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-3"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-4"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-5"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-6"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-7"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-8"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-9"},{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article-source-10"}],"author":[{"@id":"https://elacelerador.es/author/marian-vasile/#person"}],"publisher":{"@id":"https://elacelerador.es/#publisher"}},{"@type":"WebPage","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#webpage","url":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/","name":"AIOS and Bolt: a three-minute promise needs to explain the review that follows","description":"Bolt Pharmacy’s digital journey separates initial assessment, professional review and payment. For AIOS, process clarity forms part of acquisition.","inLanguage":"en-GB","isPartOf":{"@id":"https://elacelerador.es/en/#website"},"mainEntity":{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#article"},"breadcrumb":{"@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#breadcrumbs"},"primaryImageOfPage":{"@id":"https://elacelerador.es/images/aios-bolt-three-minute-promise-needs-explain-review-follows-shelves-personal-care.webp#image"}},{"@type":"BreadcrumbList","@id":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/#breadcrumbs","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://elacelerador.es/en/"},{"@type":"ListItem","position":2,"name":"Cases and research","item":"https://elacelerador.es/en/cases-and-research/"},{"@type":"ListItem","position":3,"name":"AIOS and Bolt: a three-minute promise needs to explain the review that follows","item":"https://elacelerador.es/en/cases-and-research/aios-bolt-consultation-approval-conversion/"}]}]} ```